Lupin Ltd — Capital/Financing Update 2020

Sep 28, 2020

==> picture [84 x 99] intentionally omitted <==

September 28, 2020

BSE Limited,

Department of Corporate Services, P. J. Towers, Dalal Street, Mumbai Samachar Marg, MUMBAI - 400 001.

 National Stock Exchange of India Ltd.,

Exchange Plaza, Bandra Kurla Complex, Bandra (East), MUMBAI - 400 051.

Dear Sir/Madam,

Sub: Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Enclosed is a Press Release as regards launch by the Company of Fosaprepitant for Injection, 150 mg SingleDose Vial, having received an approval from the U.S. FDA earlier.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

For LUPIN LIMITED

==> picture [90 x 51] intentionally omitted <==

R. V. SATAM COMPANY SECRETARY (ACS - 11973)

Encl- : a/a.

Registered Office: 3[rd] Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel: (91-22) 6640 2323. Corporate Identity Number: L24100MH1983PLC029442 www.lupin.com

www.lupin.com

Press Release

==> picture [68 x 70] intentionally omitted <==

BSE: 500257 NSE: LUPIN REUTERS: LUPIN.BO BLOOMBERG: LPCIN

Lupin Launches Fosaprepitant for Injection

Mumbai, Baltimore, September 28, 2020 : Pharma major Lupin Limited (Lupin) announced the launch of Fosaprepitant for Injection, 150 mg Single-Dose Vial, having received an approval from the United States Food and Drug Administration (U.S. FDA) earlier.

Fosaprepitant for Injection, 150 mg Single-Dose Vial, is the generic equivalent of Emend® for Injection, 150 mg Single-Dose Vial, of Merck Sharp & Dohme Corp. (Merck), indicated for adults in combination with other antiemetic agents, for the prevention of:

• Acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin.

• Delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC).

Fosaprepitant for Injection, 150 mg Single-Dose Vial, (RLD: Emend®) had annual sales of approximately USD 136 million in the U.S. (IQVIA MAT July 2020).

About Lupin

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.

The Company enjoys leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS) and women’s health areas. Lupin is the 3[rd] largest pharmaceutical company in the U.S. by prescriptions and 5[th] in India by global revenues. The Company invests 9.6 % of its revenues on research and development.

Lupin has fifteen manufacturing sites, seven research centers, more than 20,000 professionals working globally, and has been consistently recognized as a 'Great Place to Work' in the Biotechnology & Pharmaceuticals sector.

Please visit www.lupin.com for more information.

Follow us on Twitter: www.twitter.com/LupinGlobal | LinkedIn: www.linkedin.com/company/lupin/ Facebook: www.facebook.com/LupinWorld/

Page 1 of 2

Press Release

==> picture [68 x 70] intentionally omitted <==

BSE: 500257 NSE: LUPIN REUTERS: LUPIN.BO BLOOMBERG: LPCIN

For further information orqueriesplease contact –
Arvind Bothra Head – Investor Relations and Corporate Communications Email:arvindbothra@lupin.com Tel: +91 22 6640 8237	Manjira Sharma General Manager – Corporate Communications Email:manjirasharma@lupin.com Tel: +91 22 6640 2532

*Safe Harbor Statement

Emend® is the registered trademark of Merck Sharp & Dohme Corp

Page 2 of 2